Press releases
- Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
- Dexcom Reports First Quarter 2024 Financial Results
- Dexcom Publishes Annual Sustainability Report
- Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
- Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
- Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
- Dexcom Announces Upcoming Conference Presentation
More ▼
Key statistics
As of last trade Dexcom Inc (0A4M:LSE) traded at 130.54, -8.05% below its 52-week high of 141.97, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 130.54 |
Average volume | 692.33 |
---|---|
Shares outstanding | 397.68m |
Free float | 396.24m |
P/E (TTM) | 86.24 |
Market cap | 52.03bn USD |
EPS (TTM) | 1.52 USD |
Data delayed at least 20 minutes, as of May 21 2024 19:13 BST.
More ▼